1 / 8

Research Insights on Global Somatostatin Analogs Market Size, Growth and Forecast to 2024

The global somatostatin analogs market size was valued at USD 2,166 million in 2014 and is expected to witness a significant growth, pertaining to the rise in the prevalence of acromegaly and neuroendocrine tumors coupled with the rising investments in R&D activities.

Marsh
Télécharger la présentation

Research Insights on Global Somatostatin Analogs Market Size, Growth and Forecast to 2024

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Your Catalyst To a Lucrative Business Somatostatin Analogs Market Analysis, Size, Share, Growth, Industry Trends and Forecast to 2024 | Hexa Research “Somatostatin Analogs Market is expected to witness a significant growth, pertaining to the rise in the prevalence of acromegaly and neuroendocrine tumors coupled with the rising investments in R&D activities. 22 November 2018, The Global Somatostatin Analogs Market size to reach USD 3.1 billion by 2024, owing to the rise in the incidence rate of acromegaly and neuroendocrine tumor over the forecast period. Rising awareness, training and education by Pituitary Association of Australia and UK & Ireland Neuroendocrine Tumor Society is expected to have positive impact on the market growth in the coming years. The octreotide type analog brand Sandostatin accounted for more than 67% of the market share in 2016. The demand for octreotide is expected to show stagnant growth over the forecast period. Owing to the patent expiration of the drug Sandostatin LAR in 2014 in U.S., which was being marketed by Novartis in North America, Europe and many other countries across the globe. Rising popularity of Lanreotide brand Somatuline in the U.S. and Europe is expected to fuel the market growth. Increasing penetration and popularity of the drug in the market coupled with the rise in the use of Somatuline lanreotide for carcinoid syndrome and other related disorder is expected to provide lucrative growth opportunity for the somatostatin analogs in near future. Browse Details of Report @ https://www.hexaresearch.com/research-report/somatostatin-analogs-market Follow Us:

  2. Your Catalyst To a Lucrative Business Lanreotide is a drug used in management and treatment of acromegaly. It is also administered in the treatment of symptoms caused by carcinoid syndrome. The molecule is long acting somatostatin analog similar to octreotide. The sequence for lanreotide is H-D-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2. The drug is marketed under the brand name Somatuline and is manufactured by Ipsen. Neuroendocrine tumor (NET) segment held more than 50% of the market share in 2016. Increasing incidence rate of neuroendocrine tumors and associated diseases such as carcinoid tumors is the key factor driving the growth of the market during the forecast period. North America held more than 45% of market share in 2016. Increasing incidence of acromegaly and neuroendocrine tumor (NET) coupled with the rise in awareness and accuracy of disease diagnosis in developed economies is building a positive outlook for the acceptance of somatostatin analogs. Presence of favorable reimbursement policies, rise in the use of somatostatin analogs for treatment and, growing research and development activities in the North America is expected to have positive impact on market growth over the forecast period. Asia Pacific is expected to exhibit the fastest growth over the forecast period owing to the rise in the research and development activities in the medical field and the launch of innovative drug formulations are the main factor driving the growth of somatostatin analogs market over the forecast period. The global somatostatin analogs industry is consolidated in nature with Novartis AG and IPSEN dominating market. Companies are adopting new strategies for increasing their R&D activities and introducing new product such as signifor and signifor LAR (Pasireotide) which are gaining momentum in U.S. and European market. Competetiors are also entering into new and potential markets where they can expect the product growth in the near future. For instance, Sun Pharma Advanced Research Company Ltd., had launch somatostatin analogs product for the treatment of acromegaly in India. Hexa Research has segmented the global somatostatin analogs market report based on type, indication and region: Segmentation by type, 2014 - 2024 • Octreotide • Lanreotide • Pasireotide Segmentation by indication, 2014 - 2024 • Acromegaly Follow Us:

  3. Your Catalyst To a Lucrative Business • Neuroendocrine Tumor (NET) • Others Segmentation by region, 2014 - 2024 • North America • U.S. • Europe • Germany • UK • Asia Pacific • China • Japan • Rest of the World (RoW) Key players analyzed: • Novartis AG • Peptron • Chiasma, Inc. • Ipsen Biopharmaceuticals, Inc. • Sun Pharma Advanced Research Company Ltd. Browse Related Category Market Reports @ https://www.hexaresearch.com/research- category/pharmaceuticals-industry Follow Us:

  4. Your Catalyst To a Lucrative Business Table of Content of Somatostatin Analogs Market Chapter 1. Executive Summary Chapter 2. Methodology and Scope 2.1. Research methodology 2.2. Assumptions 2.3. List of data sources Chapter 3. Introduction 3.1. Research scope & market segmentation Chapter 4. Somatostatin Analogs Market Trends: Drivers & Opportunities 4.1. Key Industry Trends 4.1.1. Raw material trend 4.1.2. Technology trend 4.1.3. Supplier trend 4.1.4. Buyer trend 4.1.5. Regulatory trend 4.2. Market Drivers 4.3. Market Restraints 4.4. Opportunity Assessment 4.5. Raw Material Analysis 4.6. Supply Chain Analysis 4.7. PESTEL Analysis 4.8. Porter's Five Forces analysis Chapter 5. Somatostatin Analogs Market Trends, By Analogs type 5.1. Global somatostatin analogs market movement, by analogs type, 2016 & 2024 5.1.1. Octreotide 5.1.1.1. Market estimates and forecast, 2015 - 2025 (USD Million) 5.1.2. Lanreotide 5.1.2.1. Market estimates and forecast, 2015 - 2025 (USD Million) 5.1.3. Pasireotide 5.1.3.1. Market estimates and forecast, 2015 - 2025 (USD Million) Chapter 6. Somatostatin Analogs Market Trends, By Indication 6.1. Global somatostatin analogs market movement, by indication, 2014 & 2024 6.1.1. Acromegaly 6.1.1.1. Market estimates and forecast, 2015 - 2025 (USD Million) 6.1.2. Neuroendocrine Tumor (NET) Follow Us:

  5. Your Catalyst To a Lucrative Business 6.1.2.1. Market estimates and forecast, 2015 - 2025 (USD Million) 6.1.3. Others 6.1.3.1. Market estimates and forecast, 2015 - 2025 (USD Million) Chapter 7. Somatostatin Analogs Market Trends, By Region 7.1. Global somatostatin analogs market movement, by region, 2014 & 2024 7.1.1. North America 7.1.1.1. Market estimates and forecast, 2015 - 2025 (USD Million) 7.1.1.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million) 7.1.1.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million) 7.1.2. Europe 7.1.2.1. Market estimates and forecast, 2015 - 2025 (USD Million) 7.1.2.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million) 7.1.2.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million) 7.1.3. Asia-Pacific 7.1.3.1. Market estimates and forecast, 2015 - 2025 (USD Million) 7.1.3.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million) 7.1.3.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million) 7.1.4. Rest of the World (RoW) 7.1.4.1. Market estimates and forecast, 2015 - 2025 (USD Million) 7.1.4.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million) 7.1.4.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million) Chapter 8. Key Country Markets 8.1. U.S. 8.1.1. Market estimates and forecast, 2015 - 2025 (USD Million) 8.1.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million) 8.1.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million) 8.2. Germany 8.2.1. Market estimates and forecast, 2015 - 2025 (USD Million) 8.2.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million) 8.2.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million) 8.3. UK 8.3.1. Market estimates and forecast, 2015 - 2025 (USD Million) 8.3.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million) 8.3.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million) 8.4. China 8.4.1. Market estimates and forecast, 2015 - 2025 (USD Million) Follow Us:

  6. Your Catalyst To a Lucrative Business 8.4.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million) 8.4.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million) 8.5. Japan 8.5.1. Market estimates and forecast, 2015 - 2025 (USD Million) 8.5.2. Market estimates and forecast, by analogs type, 2015 - 2025 (USD Million) 8.5.3. Market estimates and forecast, by indication, 2015 - 2025 (USD Million) Chapter 9. Competitive Landscape 9.1. Company Market Share Analysis,2016 9.2. Strategic framework 9.3. Company profiles 9.3.1. Novartis AG 9.3.1.1. Company Overview 9.3.1.2. Financial Performance 9.3.1.3. Product Benchmarking 9.3.1.4. SWOT 9.3.1.5. Recent Initiatives 9.3.1.6. Future Outlook and Strategies 9.3.2. Peptron 9.3.2.1. Company Overview 9.3.2.2. Financial Performance 9.3.2.3. Product Benchmarking 9.3.2.4. SWOT 9.3.2.5. Recent Initiatives 9.3.2.6. Future Outlook and Strategies 9.3.3. Chaisma, Inc. 9.3.3.1. Company Overview 9.3.3.2. Financial Performance 9.3.3.3. Product Benchmarking 9.3.3.4. SWOT 9.3.3.5. Recent Initiatives 9.3.3.6. Future Outlook and Strategies 9.3.4. Ipsen Biopharmaceuticals, Inc. 9.3.4.1. Company Overview 9.3.4.2. Financial Performance 9.3.4.3. Product Benchmarking 9.3.4.4. SWOT Follow Us:

  7. Your Catalyst To a Lucrative Business 9.3.4.5. Recent Initiatives 9.3.4.6. Future Outlook and Strategies 9.3.5. Sun Pharma Advanced Research Company Ltd. 9.3.5.1. Company Overview 9.3.5.2. Financial Performance 9.3.5.3. Product Benchmarking 9.3.5.4. SWOT 9.3.5.5. Recent Initiatives 9.3.5.6. Future Outlook and Strategies 9.3.6. List of other vendors Follow Us:

  8. Your Catalyst To a Lucrative Business About Us: Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Us: Ryan Shaw Hexa Research Felton Office Plaza 6265 Highway 9 Felton, California 95018 United States Phone: +1-800-489-3075 Email: sales@hexaresearch.com Website - http://www.hexaresearch.com/ Follow Us:

More Related